Free Trial

Sarepta Therapeutics (SRPT) 10K Form and Latest SEC Filings 2026

Sarepta Therapeutics logo
$20.80 -2.23 (-9.68%)
Closing price 05/7/2026 04:00 PM Eastern
Extended Trading
$20.76 -0.05 (-0.22%)
As of 05:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Sarepta Therapeutics SEC Filings & Recent Activity

Sarepta Therapeutics (NASDAQ:SRPT) has submitted 433+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Sarepta Therapeutics's financial statements. The most recent filing was a Form 10-Q submitted on May 6, 2026.

Form 4
Sarepta Therapeutics, Inc. Reports Ownership Change on Mar. 13, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

10-Q
Sarepta Therapeutics Files Quarterly Report on May. 6, 2026

The 10-Q contains Sarepta Therapeutics's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Sarepta Therapeutics SEC Filing History

Browse Sarepta Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/06/2026 3:01 PM
Sarepta Therapeutics (873303) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/30/2026 12:09 PM
Sarepta Therapeutics (873303) Subject
VANGUARD CAPITAL MANAGEMENT LLC (2100119) Filed by
Form SCHEDULE 13G
04/29/2026 2:13 PM
Sarepta Therapeutics (873303) Subject
VANGUARD PORTFOLIO MANAGEMENT LLC (2100121) Filed by
Form SCHEDULE 13G
04/24/2026 3:21 PM
Sarepta Therapeutics (873303) Filer
Form ARS
03/13/2026 7:01 PM
Rothfuss Cristin (2046214) Reporting
Sarepta Therapeutics (873303) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/13/2026 7:03 PM
Mayo Stephen (1849061) Reporting
Sarepta Therapeutics (873303) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/13/2026 7:05 PM
Rodino-Klapac Louise (1836218) Reporting
Sarepta Therapeutics (873303) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/13/2026 7:07 PM
Sarepta Therapeutics (873303) Issuer
Wong Ryan Ho-Yan (2079673) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/13/2026 7:09 PM
Estepan Ian Michael (1836254) Reporting
Sarepta Therapeutics (873303) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/12/2026 3:27 PM
Mayo Stephen (1849061) Reporting
Sarepta Therapeutics (873303) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/11/2026 7:01 PM
Estepan Ian Michael (1836254) Reporting
Sarepta Therapeutics (873303) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/11/2026 7:04 PM
Rodino-Klapac Louise (1836218) Reporting
Sarepta Therapeutics (873303) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/11/2026 7:07 PM
Rothfuss Cristin (2046214) Reporting
Sarepta Therapeutics (873303) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/11/2026 7:08 PM
Sarepta Therapeutics (873303) Issuer
Wong Ryan Ho-Yan (2079673) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 7:02 PM
Rodino-Klapac Louise (1836218) Reporting
Sarepta Therapeutics (873303) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 7:04 PM
Estepan Ian Michael (1836254) Reporting
Sarepta Therapeutics (873303) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 7:05 PM
Sarepta Therapeutics (873303) Issuer
Wong Ryan Ho-Yan (2079673) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 7:07 PM
Rothfuss Cristin (2046214) Reporting
Sarepta Therapeutics (873303) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/02/2026 7:00 AM
Estepan Ian Michael (1836254) Reporting
Sarepta Therapeutics (873303) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/02/2026 6:02 AM
Sarepta Therapeutics (873303) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/27/2026 7:03 PM
Rodino-Klapac Louise (1836218) Reporting
Sarepta Therapeutics (873303) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/27/2026 7:05 PM
Estepan Ian Michael (1836254) Reporting
Sarepta Therapeutics (873303) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2026 10:52 AM
AQR CAPITAL MANAGEMENT LLC (1167557) Filed by
Sarepta Therapeutics (873303) Subject
Form SCHEDULE 13G
02/12/2026 7:57 PM
Sarepta Therapeutics (873303) Filer
Form 13F-HR
Initial Quarterly Form 13F Holdings report filed by institutional managers
01/29/2026 7:04 PM
BEHRENS M KATHLEEN (1211701) Reporting
Sarepta Therapeutics (873303) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/29/2026 7:05 PM
Nicaise Claude (1644162) Reporting
Sarepta Therapeutics (873303) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 11:30 AM
BlackRock, Inc. (2012383) Filed by
Sarepta Therapeutics (873303) Subject
Form SCHEDULE 13G/A
01/12/2026 11:05 AM
Sarepta Therapeutics (873303) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/19/2025 3:40 PM
Chambers Michael Andrew (1932527) Reporting
Sarepta Therapeutics (873303) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2025 3:34 PM
Sarepta Therapeutics (873303) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/18/2025 7:05 PM
Estepan Ian Michael (1836254) Reporting
Sarepta Therapeutics (873303) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2025 4:05 PM
Estepan Ian Michael (1836254) Reporting
Sarepta Therapeutics (873303) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/11/2025 6:13 AM
Sarepta Therapeutics (873303) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/10/2025 7:05 PM
Sarepta Therapeutics (873303) Issuer
Wong Ryan Ho-Yan (2079673) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/09/2025 7:30 PM
INGRAM DOUGLAS S (1190644) Reporting
Sarepta Therapeutics (873303) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/08/2025 6:33 AM
Sarepta Therapeutics (873303) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/02/2025 7:02 PM
Rothfuss Cristin (2046214) Reporting
Sarepta Therapeutics (873303) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/19/2025 7:05 PM
Rodino-Klapac Louise (1836218) Reporting
Sarepta Therapeutics (873303) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/14/2025 3:08 PM
D. E. SHAW & CO, L.P. (1009268) Filed by
Sarepta Therapeutics (873303) Subject
Form SCHEDULE 13G/A
11/10/2025 7:54 AM
Sarepta Therapeutics (873303) Subject
STATE STREET CORP (93751) Filed by
STATE STREET CORP (93751) Filed by
Form SCHEDULE 13G
11/03/2025 3:18 PM
Sarepta Therapeutics (873303) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/08/2025 10:06 AM
Sarepta Therapeutics (873303) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
09/05/2025 8:30 PM
Rothfuss Cristin (2046214) Reporting
Sarepta Therapeutics (873303) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/05/2025 8:30 PM
Estepan Ian Michael (1836254) Reporting
Sarepta Therapeutics (873303) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/05/2025 8:30 PM
Sarepta Therapeutics (873303) Issuer
Wong Ryan Ho-Yan (2079673) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/05/2025 8:30 PM
Rodino-Klapac Louise (1836218) Reporting
Sarepta Therapeutics (873303) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/29/2025 3:18 PM
Sarepta Therapeutics (873303) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/21/2025 6:07 AM
Sarepta Therapeutics (873303) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/15/2025 4:28 PM
ARROWHEAD PHARMACEUTICALS, INC. (879407) Subject
Sarepta Therapeutics (873303) Filed by
Form SCHEDULE 13D/A
08/13/2025 7:55 PM
ARROWHEAD PHARMACEUTICALS, INC. (879407) Subject
Sarepta Therapeutics (873303) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/13/2025 11:49 AM
Capital International Investors (1562230) Filed by
Sarepta Therapeutics (873303) Subject
Form SCHEDULE 13G/A
08/06/2025 7:02 PM
Estepan Ian Michael (1836254) Reporting
Sarepta Therapeutics (873303) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/06/2025 7:03 PM
Arif Bilal (1959750) Reporting
Sarepta Therapeutics (873303) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/06/2025 7:01 PM
Rodino-Klapac Louise (1836218) Reporting
Sarepta Therapeutics (873303) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/04/2025 7:00 PM
Sarepta Therapeutics (873303) Issuer
Wong Ryan Ho-Yan (2079673) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/04/2025 7:10 PM
Sarepta Therapeutics (873303) Issuer
Wong Ryan Ho-Yan (2079673) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/25/2025 7:14 PM
D. E. SHAW & CO, L.P. (1009268) Filed by
Sarepta Therapeutics (873303) Subject
Form SCHEDULE 13G/A
07/21/2025 6:30 AM
Sarepta Therapeutics (873303) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/16/2025 3:11 PM
Sarepta Therapeutics (873303) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/06/2025 3:30 PM
Sarepta Therapeutics (873303) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/19/2025 6:32 AM
Barry Richard (1562371) Reporting
Sarepta Therapeutics (873303) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/15/2025 6:00 AM
Barry Richard (1562371) Reporting
Sarepta Therapeutics (873303) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)

Sarepta Therapeutics SEC Filings - Frequently Asked Questions

Sarepta Therapeutics (SRPT) has submitted 433+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Sarepta Therapeutics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Sarepta Therapeutics's financial statements page.

The most recent filing was a Form 10-Q submitted on May 6, 2026. This was a quarterly financial update for 2025.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:SRPT) was last updated on 5/8/2026 by MarketBeat.com Staff.
From Our Partners